Literature DB >> 2382828

Automated enzymatic measurement of adenosine deaminase isoenzyme activities in serum.

T Muraoka1, T Katsuramaki, H Shiraishi, M M Yokoyama.   

Abstract

We developed a simple, rapid, and automated method for simultaneous measurement of adenosine deaminase (ADA, EC 3.5.4.4) isoenzymes in human serum, based on their apparent difference in Ki values for erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) as inhibitor. Serum ADA was partially purified by CM-Sephadex, gel-filtration, and affinity chromatography into two types of isoenzymes, designated ADA1 (300 kDa) and ADA2 (120 kDa). Because ADA2 has a higher Km for adenosine and higher Ki values for EHNA than does ADA1, the activity of ADA1 is almost completely inhibited by EHNA at 0.1 mM (analytical recovery 4.1%), whereas ADA2 is practically unaffected (analytical recovery 94.8%) by that concentration of EHNA. We measured the activities of ADA2 and total ADA in the presence and absence of 0.1 mM EHNA. ADA1 activities were calculated by subtracting the activity of ADA2 from that of total ADA. The mean within-assay CV was 5.7% for ADA1 and 2.7% for ADA2. The interassay CV was 2.8% for ADA1 and 3.1% for ADA2. Results of the present method correlated well (r = 0.9026 for ADA1, 0.9438 for ADA2) with those of the ion-exchange chromatography method. The upper limits of the reference intervals, as calculated from data for 320 healthy donors, are 7.2 U/liter for ADA1, and 14.6 U/liter for ADA2. This method is suitable for analysis of large numbers of samples in clinical laboratories for routine monitoring of the activities of ADA isoenzymes in serum.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2382828     DOI: 10.1016/0003-2697(90)90455-i

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  14 in total

1.  Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern.

Authors:  Reza Saghiri; Niloufar Ghashghai; Shafieh Movaseghi; Pegah Poursharifi; Shohreh Jalilfar; Manijeh Ahmadi Bidhendi; Leila Ghazizadeh; Mina Ebrahimi-Rad
Journal:  Rheumatol Int       Date:  2011-02-25       Impact factor: 2.631

2.  Adenosine deaminase isoenzyme levels in patients with human T-cell lymphotropic virus type 1 and human immunodeficiency virus type 1 infections.

Authors:  I Tsuboi; K Sagawa; S Shichijo; M M Yokoyama; D W Ou; M D Wiederhold
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

3.  Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.

Authors:  Pui Y Lee; Grant S Schulert; Scott W Canna; Yuelong Huang; Jacob Sundel; Ying Li; Kacie J Hoyt; Rachel B Blaustein; Alexandra Wactor; Thuy Do; Olha Halyabar; Margaret H Chang; Fatma Dedeoglu; Siobhan M Case; Esra Meidan; Mindy S Lo; Robert P Sundel; Edward T Richardson; Jane W Newburger; Michael S Hershfield; Mary Beth Son; Lauren A Henderson; Peter A Nigrovic
Journal:  Ann Rheum Dis       Date:  2019-11-09       Impact factor: 19.103

4.  Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency.

Authors:  Donald B Kohn; Claire Booth; Kit L Shaw; Jinhua Xu-Bayford; Elizabeth Garabedian; Valentina Trevisan; Denise A Carbonaro-Sarracino; Kajal Soni; Dayna Terrazas; Katie Snell; Alan Ikeda; Diego Leon-Rico; Theodore B Moore; Karen F Buckland; Ami J Shah; Kimberly C Gilmour; Satiro De Oliveira; Christine Rivat; Gay M Crooks; Natalia Izotova; John Tse; Stuart Adams; Sally Shupien; Hilory Ricketts; Alejandra Davila; Chilenwa Uzowuru; Amalia Icreverzi; Provaboti Barman; Beatriz Campo Fernandez; Roger P Hollis; Maritess Coronel; Allen Yu; Krista M Chun; Christian E Casas; Ruixue Zhang; Serena Arduini; Frances Lynn; Mahesh Kudari; Andrea Spezzi; Marco Zahn; Rene Heimke; Ivan Labik; Roberta Parrott; Rebecca H Buckley; Lilith Reeves; Kenneth Cornetta; Robert Sokolic; Michael Hershfield; Manfred Schmidt; Fabio Candotti; Harry L Malech; Adrian J Thrasher; H Bobby Gaspar
Journal:  N Engl J Med       Date:  2021-05-11       Impact factor: 91.245

5.  The binding site of human adenosine deaminase for CD26/Dipeptidyl peptidase IV: the Arg142Gln mutation impairs binding to cd26 but does not cause immune deficiency.

Authors:  E Richard; F X Arredondo-Vega; I Santisteban; S J Kelly; D D Patel; M S Hershfield
Journal:  J Exp Med       Date:  2000-11-06       Impact factor: 14.307

6.  Diagnostic accuracy of tumor necrosis factor-alpha, interferon-gamma, interleukin-10 and adenosine deaminase 2 in differential diagnosis between tuberculous pleural effusion and malignant pleural effusion.

Authors:  Mingying Li; Helin Wang; Xia Wang; Jian Huang; Junxiang Wang; Xiue Xi
Journal:  J Cardiothorac Surg       Date:  2014-07-01       Impact factor: 1.637

Review 7.  Vasculopathy, Immunodeficiency, and Bone Marrow Failure: The Intriguing Syndrome Caused by Deficiency of Adenosine Deaminase 2.

Authors:  Pui Y Lee
Journal:  Front Pediatr       Date:  2018-10-18       Impact factor: 3.418

8.  Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2 Deficiency.

Authors:  Stuart G Tangye; Isabelle Meyts; Jin Yan Yap; Leen Moens; Ming-Wei Lin; Alisa Kane; Anthony Kelleher; Catherine Toong; Kathy H C Wu; William A Sewell; Tri Giang Phan; Georgina E Hollway; Karen Enthoven; Paul E Gray; Jose Casas-Martin; Carine Wouters; Lien De Somer; Michael Hershfield; Giorgia Bucciol; Selket Delafontaine; Cindy S Ma
Journal:  J Clin Immunol       Date:  2021-10-17       Impact factor: 8.317

Review 9.  Therapeutic Perspectives of Adenosine Deaminase Inhibition in Cardiovascular Diseases.

Authors:  Barbara Kutryb-Zajac; Paulina Mierzejewska; Ewa M Slominska; Ryszard T Smolenski
Journal:  Molecules       Date:  2020-10-12       Impact factor: 4.411

10.  Characterization of total adenosine deaminase activity (ADA) and its isoenzymes in saliva and serum in health and inflammatory conditions in four different species: an analytical and clinical validation pilot study.

Authors:  María Dolores Contreras-Aguilar; Asta Tvarijonaviciute; Ingrida Monkeviciene; María Martín-Cuervo; Luis Guillermo González-Arostegui; Lorena Franco-Martínez; José Joaquín Cerón; Fernando Tecles; Damián Escribano
Journal:  BMC Vet Res       Date:  2020-10-12       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.